The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...

Members of Tiziana's senior management team will also attend the forum and be available for one-on-one meetings with investors, partners, and other stakeholders. The 9th Annual Neuroscience Innovation ...

This Review summarizes the results from preclinical and clinical studies that use CD3-specific monoclonal antibody therapy and highlights future combination opportunities to enhance the efficacy of ...

Multiple Myeloma (MM) is the second most common hematological malignancy that originates from plasma cells. Over the last 20 years, treatment for patients of MM has advanced significantly; but despite ...

Figure 1: CD3-specific antibody treatment increases systemic TGF-β, which requires the presence of macrophages and iDCs. Figure 2: iDCs produce TGF-β upon ingestion of apoptotic cells and induce Foxp3 ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...

ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...